PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30153066-7	2018	Treatment of GSTP-null mice with the JNK inhibitor 1,9-pyrazoloanthrone (SP600125) significantly attenuated pyruvate-induced hepatic gluconeogenesis and significantly altered correlations between hepatic cytokine mRNAs and metabolic outcomes in GSTP-null mice.	Pyruvic Acid	108-116	mitogen-activated protein kinase 8	Homo sapiens	37-40	
17982276-9	2007	Treatment of pyruvate synergistically increased osteoclastogenesis through the activation of RANKL-stimulated signals (ERK and JNK).	Pyruvic Acid	13-21	mitogen-activated protein kinase 8	Homo sapiens	127-130	
10982848-3	2000	Mitochondrial metabolism of pyruvate is demonstrated to activate the c-Jun N-terminal kinase (JNK).	Pyruvic Acid	28-36	mitogen-activated protein kinase 8	Homo sapiens	69-92	
10982848-3	2000	Mitochondrial metabolism of pyruvate is demonstrated to activate the c-Jun N-terminal kinase (JNK).	Pyruvic Acid	28-36	mitogen-activated protein kinase 8	Homo sapiens	94-97	
33230593-8	2021	Mechanistically, a high extracellular lactate-to-pyruvate ratio decreases the activation of JNK and Bax under oxidative stress, thereby inhibiting the intrinsic apoptotic pathway.	Pyruvic Acid	49-57	mitogen-activated protein kinase 8	Homo sapiens	92-95